Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Nat Commun ; 7: 12308, 2016 07 25.
Artículo en Inglés | MEDLINE | ID: mdl-27453292

RESUMEN

Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in tumours, we conduct a high-throughput screen for oxygen consumption rate (OCR) reduction and identify a number of drugs with this property. For this study we focus on the anti-malarial, atovaquone. Atovaquone rapidly decreases the OCR by more than 80% in a wide range of cancer cell lines at pharmacological concentrations. In addition, atovaquone eradicates hypoxia in FaDu, HCT116 and H1299 spheroids. Similarly, it reduces hypoxia in FaDu and HCT116 xenografts in nude mice, and causes a significant tumour growth delay when combined with radiation. Atovaquone is a ubiquinone analogue, and decreases the OCR by inhibiting mitochondrial complex III. We are now undertaking clinical studies to assess whether atovaquone reduces tumour hypoxia in patients, thereby increasing the efficacy of radiotherapy.


Asunto(s)
Antimaláricos/farmacología , Atovacuona/farmacología , Tolerancia a Radiación/efectos de los fármacos , Hipoxia Tumoral/efectos de los fármacos , Animales , Biguanidas/farmacología , Complejo III de Transporte de Electrones/metabolismo , Ensayos Analíticos de Alto Rendimiento , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Ratones Endogámicos BALB C , Ratones Desnudos , Consumo de Oxígeno/efectos de los fármacos , Pirimidinas/biosíntesis , Esferoides Celulares/efectos de los fármacos , Esferoides Celulares/metabolismo , Esferoides Celulares/patología , Células Tumorales Cultivadas
2.
Mol Imaging Biol ; 15(6): 693-702, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23632953

RESUMEN

PURPOSE: Profound changes of the vasculature in tumors critically impact drug delivery and therapy response. We aimed at developing a procedure to monitor morphological and functional parameters of the vasculature in subcutaneous xenograft models commonly applied for therapy testing by using probe-based confocal laser endomicroscopy. PROCEDURES: By monitoring various normal and diseased tissues, we established an experimental and analytical set-up to systematically analyze tracer extravasation from the microvasculature. Application of the approach in two xenograft models (HCT-116 and SW620) was realized consecutively throughout tumor growth. RESULTS: The incidence of dilated vessels increased with xenograft size in both models while macromolecule extravasation and tracer accumulation in the tumor tissue, respectively, was significantly reduced throughout growth. The development of dilated/ultradilated vessels correlated with tracer extravasation only in the HCT-116 but not the SW620 model. The underlying mechanisms are still ambiguous and discussed. CONCLUSIONS: Our findings clearly indicate that both xenograft type and size matter for drug delivery and therapy testing.


Asunto(s)
Permeabilidad Capilar , Extravasación de Materiales Terapéuticos y Diagnósticos/patología , Microscopía Confocal/métodos , Neovascularización Patológica/patología , Animales , Femenino , Células HCT116 , Humanos , Ratones , Ratones Endogámicos C57BL , Músculos/irrigación sanguínea , Músculos/patología , Neoplasias Experimentales , Lengua/irrigación sanguínea , Lengua/patología , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Int J Radiat Biol ; 85(11): 989-1001, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19895276

RESUMEN

PURPOSE: Tumour lactate levels have been shown to correlate with high radioresistance in tumour models in vivo. The study aimed to evaluate the impact of pathophysiological extracellular lactate concentrations and acidosis on the in vitro survival and radioresponse of various cancer cell lines. MATERIALS AND METHODS: HCT-116, HT29 (colorectal) and FaDu (HNSCC) carcinoma cells were studied. Lactate release rates were determined, and expression of the monocarboxylate transporter MCT1 and its cofactor CD147 were monitored by immunofluorescence and flow cytometry. Colony formation was compared for cells exposed to 20 mM exogenous lactate, acidosis (pH 6.4) and lactate plus acidosis relative to control and dose response curves (0.5-10 Gy) were documented. RESULTS: All cell lines expressed MCT1 and CD147 and showed comparable lactate release rates. High lactate levels and acidosis slightly decreased HCT-116 colony forming capacity. This effect was neither additive nor did it affect radioresponse. Clonogenic survival of HT29 cells, however, was critically reduced in a lactate-enriched or acidic milieu and a synergistic effect was observed. Here, both conditions enhanced radiosensitivity. Exogenous lactate also impaired colony formation of FaDu cells but acidosis was ineffective. This cell line was more susceptible to irradiation under lactate exposure independent of pH. CONCLUSIONS: Tumour cell behaviour and radioresponse in a lactate environment is multifaceted. The consideration of lactate accumulation as a parameter affecting radiotherapeutic intervention and as a target for new therapeutic strategies is interesting but requires extended mechanistic studies.


Asunto(s)
Carcinoma/tratamiento farmacológico , Carcinoma/radioterapia , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/efectos de la radiación , Ácido Láctico/farmacología , Tolerancia a Radiación/efectos de los fármacos , Acidosis/metabolismo , Acidosis/patología , Basigina/metabolismo , Carcinoma/metabolismo , Carcinoma/patología , Línea Celular Tumoral , Glucosa/metabolismo , Células HCT116 , Células HT29 , Humanos , Concentración de Iones de Hidrógeno , Técnicas In Vitro , Ácido Láctico/metabolismo , Transportadores de Ácidos Monocarboxílicos/metabolismo , Simportadores/metabolismo , Ensayo de Tumor de Célula Madre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA